News

Glutamate Receptor Ionotropic NMDA 2B Research Report: Competitor, Under Development Projects, Mergers and Acquisition, Discontinued Projects and more

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) – Glutamate receptor subunit epsilon-2 or N-methyl D-aspartate receptor subtype 2B (NMDAR2B or NR2B) is a protein encoded by the GRIN2B gene. It is mediated by glycine. It acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them resulting in an irreversible neuronal death.

Report Source: https://www.themarketreports.com/report/glutamate-receptor-ionotropic-nmda-2b-pipeline-review-h1

Scope

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glutamate Receptor Ionotropic NMDA 2B targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glutamate Receptor Ionotropic NMDA 2B targeted therapeutics

Purchase this report at: https://www.themarketreports.com/report/buy-now/1482491

Reasons To Buy

  • Identify and understand the targeted therapy areas and indications for Glutamate Receptor Ionotropic NMDA 2B
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glutamate Receptor Ionotropic NMDA 2B development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

  • Bristol-Myers Squibb Co
  • Cadent Therapeutics Inc
  • Cerecor Inc
  • Johnson & Johnson
  • NeurOp Inc
  • Novartis AG
  • Shionogi & Co Ltd

Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/1482491